| アブストラクト | INTRODUCTION: Since being designated as medicines by World Health Organization (WHO), blood components are subject to pharmacovigilance reporting. Using VigiBase, the WHO global database of individual case safety reports (ICSRs), we characterized reports of adverse reactions for all blood products. STUDY DESIGN AND METHODS: ICSRs involving blood products as the suspected medicine in VigiBase between 1968 and 2021 were extracted. MedDRA preferred terms and the International Society of Blood Transfusion haemovigilance definitions were used to stratify adverse reactions. Descriptive statistics were used to characterize ICSR demographics. RESULTS: A total of 111,033 ICSRs containing 577,577 suspected adverse reactions with 6152 MedDRA preferred terms were reported for 34 blood products. There were 12,153 (10.9%) reports for blood components, 98,135 (88.4%) reports for plasma-derived medicines, and 745 (0.7%) reports for recombinant products. The majority of reports (21.0% and 19.7%, respectively) were from patients aged 45-64 and over 65 years. The Americas contributed the most ICSRs (49.7%). Top reported suspected adverse reactions were for the following MedDRA preferred terms: headache (3.5%), pyrexia (2.8%), chills (2.8%), dyspnoea (1.8%), and nausea (1.8%). CONCLUSION: VigiBase already has a large number of reports on blood products. When compared to other existing haemovigilance databases, our study found reports from a broader range of countries and reporters. This may provide us with new perspectives, but for VigiBase to reach its full potential in haemovigilance some alterations in what is captured in reports are required. |
|---|
| ジャーナル名 | Transfusion |
|---|
| Pubmed追加日 | 2023/3/31 |
|---|
| 投稿者 | Samukange, Washington T; Lu, Ting-An; Souverein, Patrick C; Gardarsdottir, Helga; Mantel-Teeuwisse, Aukje K |
|---|
| 組織名 | Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for;Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht,;the Netherlands.;Major Policy and Coordination Division, Paul Ehrlich Institut, Langen, Germany.;Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the;Netherlands.;Department of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36994873/ |
|---|
